|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
200 Greenhill Rd, Eastwood, South Australia 5063, AU
|
|
Bionomics (Nasdaq: BNOX, ASX:BNO) is a clinical-stage biopharmaceutical developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need. Bionomics is advancing its lead product candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder and chronic treatment of Post-Traumatic Stress Disorder.
Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other central nervous system conditions.
To learn more about the company, pipeline and collaboration opportunities, visit us at www.bionomics.com.au.
|
Bionomics Ltd Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
66.67%
|
The widely used Bionomics Ltd email format is {f}{last} (e.g. [email protected]) with 66.67% adoption across the company.
To contact Bionomics Ltd customer service number in your country click here to find.
Deborah Rathjen is the CEO of Bionomics Ltd. To contact Deborah Rathjen email at [email protected]. Or you may call + 61 418 160 425
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.